Press Release: Availability of the revised financial statements for Sanofi excluding Opella
06 Dicembre 2024 - 7:30AM
UK Regulatory
Press Release: Availability of the revised financial statements for
Sanofi excluding Opella
Availability of the revised financial
statements for Sanofi excluding Opella
Paris, France – December 6,
2024. Following the press release on October 21, 2024 and
the plan to transfer a 50% controlling stake in Opella (consumer
healthcare division) to CD&R, the revised financial statements
for Sanofi reflecting the new scope, excluding Opella, are now
available on the "Investors" section of sanofi.com in one
convenient spreadsheet file.
The adjustments to the financial statements
reclassify Opella’s business as discontinued operations, in line
with the planned transition of Sanofi to a focused, science-driven
biopharma company.
The revised financial data which were reviewed
by Sanofi’s auditors, include details on sales, business net income
and reported IFRS financials of Sanofi excluding Opella. From Q4
2024 and until the closing of the transaction, the profit or loss
of Opella, net of tax, is included in “Net income / (loss) from
discontinued operations” in the Sanofi income statement. This
classification as discontinued operations as well as the full
financial data apply to all previous quarters of 2024 and for
comparison to all quarters of 2023.
Sanofi's Q4 2024 results, reflecting the new
scope excluding Opella, are expected to be published
on January 30, 2025.
About Sanofi
We are an innovative global healthcare company, driven by one
purpose: we chase the miracles of science to improve people’s
lives. Our team, across some 100 countries, is dedicated to
transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing
treatment options and life-saving vaccine protection to millions of
people globally, while putting sustainability and social
responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.com
Evan Berland | + 1 215 432 0234 |
evan.berland@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81
| leo.lebourhis@sanofi.com
Nicolas Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.com
Victor Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.com
Timothy Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Investor Relations
Thomas Kudsk Larsen | + 44 75 45 51 36 93|
thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.com
Felix Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.com
Keita Browne | +1 781 249 1766 |
keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 |
tarik.elgoutni@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 |
thibaud.chatelet@sanofi.com
Forward-looking statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions, and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that pandemics or other
global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one
of them, as well as on our employees and on the global economy as a
whole. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2023. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements.
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Dic 2023 a Dic 2024
